Sign In
Buy RHHBY
$54.64
-0.630 (-1.14%)
At Close: Jul 31, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced detailed results from four Phase III studies of its investigational bi
Oxford study finds Roche's Actemra reduces Covid deaths
10:51am, Thursday, 11'th Feb 2021
CNBC's Meg Tirrell reports on results from a new Oxford study that shows how Roche's drug Actemra reduces Covid deaths.
Roche's Fourth Quarter Was Ugly, But The Long-Term Quality Remains Sound
11:53am, Wednesday, 10'th Feb 2021
Roche reported a big miss in the fourth quarter, driven by a double-digit miss in Pharmaceuticals, as biosimilars and COVID-19 hit the company hard.
Coherus Deal Signals Pivot to New and Crowded Market
05:00pm, Monday, 08'th Feb 2021
Shares of Redwood City, California-based Coherus BioSciences Inc. (NASDAQ:CHRS) are up about 13% just a week after announcing it has cut a $150 million deal with Chinese drugmaker Junshi Biosciences C
Basel, 8 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to their Elecsys® GDF-15 assay
Roche Working ‘Day and Night' on Covid Treatment Production: CEO
05:28pm, Friday, 05'th Feb 2021
Feb.04 -- Roche Holding AG Chief Executive Officer Severin Schwan said the company is working “day and night” to boost production capacity for the Covid-19 antibody cocktail it's developing with R
Roche Unit Spark Therapeutics' Hemophilia A Gene Therapy Shows Durable Benefit In Early-Stage Study
12:37pm, Friday, 05'th Feb 2021
Spark Therapeutics, a unit of Roche Holdings (OTC: RHHBY), has announced preliminary data from part one of the ongoing Phase 1/2 trial evaluating SPK-8016 in hemophilia A, a genetic deficiency
Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19
12:07pm, Friday, 05'th Feb 2021
Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Preliminary data from four participants who received investigational SPK-8016 at a dose of 5X10 11 vg/kg and have no history of FVIII inhibitors show no serious adverse events and stable and durable f
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
12:15am, Friday, 05'th Feb 2021
Roche Holding AG (RHHBY) CEO Severin Schwan on Q4 2020 Results - Earnings Call Transcript
The Hanover Insurance Group's (THG) CEO Jack Roche on Q4 2020 Results - Earnings Call Transcript
02:45pm, Thursday, 04'th Feb 2021
The Hanover Insurance Group's (THG) CEO Jack Roche on Q4 2020 Results - Earnings Call Transcript
COVID-19 Test Business Fuels Roche Q4 Sales, Hikes Dividend
07:31am, Thursday, 04'th Feb 2021
Roche Holdings (OTC: RHHBF) reports a fourth-quarter lift driven by double-digit growth in the diagnostics business, propelled by its 15 COVID-19 tests portfolio. However, the main pharmaceuticals bus
Roche CEO says Covid testing demand to remain high in 2021
03:31am, Thursday, 04'th Feb 2021
Roche CEO Severin Schwan discusses the company's full-year 2020 earnings, the pharma giant's Covid-19 tests, and the outlook for the pandemic in 2021.
Roche reports solid results in 2020
01:00am, Thursday, 04'th Feb 2021
Basel, 4 February 2021
Bolt Biotherapeutics Aims For $150 Million U.S. IPO
01:53pm, Tuesday, 02'nd Feb 2021
Bolt Biotherapeutics has filed proposed terms for a $150 million IPO. The firm is developing antibody conjugate treatments for various cancers.
